Monday, October 8, 2018, Rockville, MD - Insilico Medicine, a Rockville-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and aging research, is pleased to announce that Polina Mamoshina, a senior research scientist at Insilico Medicine will present at the Women at GTC panel on "Leadership in the age of AI". Polina was the lead author on one of the highest-cited papers in and appeared on the cover of the special issue of the American Chemical Society's Molecular Pharmaceutics dedicated to Deep Learning for Drug Discovery.
The session is dedicated to the women at GTC titled "Leadership in the age of AI" will take place on the 10th of October, 2018 during NVIDIA GPU Technology Conference (GTC) Europe that is a part of the largest global series of events focused on artificial intelligence and its applications across many important fields. This session explores the topic of "Leadership In The Age of AI". All GTC delegates who support diversity and inclusion in the tech world are invited to join.
"I think it is really timely for us to have this conversation. Nvidia organized a truly wonderful event. It is also really important for this panel to be a part of the one of the largest tech show in the world. I am really looking forward to sharing my experience and perspectives as a female researcher and deep learning scientist", said Polina Mamoshina, a senior research scientist at Insilico Medicine.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact.
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning culminating in a special issue on deep learning. The paper published in Molecular Pharmaceutics in 2016 demonstrated the first proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients.
For further information, images or interviews, please contact:
About NVIDIA's GTC
NVIDIA's GPU Technology Conference (GTC) Europe is part of the largest global series of events focused on artificial intelligence and its applications across many important fields.
About Insilico Medicine, Inc
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered at in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company and its scientists is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https:/